Scarica l'app Stockscreener
2.15
10.04%
-0.24
Dopo l'orario di chiusura:
2.19
0.04
+1.86%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MXCT Giù?
Forum
Previsione
Precedente Chiudi:
$2.39
Aprire:
$2.39
Volume 24 ore:
822.47K
Relative Volume:
0.93
Capitalizzazione di mercato:
$228.59M
Reddito:
$45.44M
Utile/perdita netta:
$-35.43M
Rapporto P/E:
-6.3235
EPS:
-0.34
Flusso di cassa netto:
$-25.39M
1 W Prestazione:
-6.93%
1M Prestazione:
-19.48%
6M Prestazione:
-39.94%
1 anno Prestazione:
-53.16%
Intervallo 1D:
$2.13
$2.40
Intervallo di 1 settimana:
$2.13
$2.40
Portata 52W:
$2.10
$5.26
Maxcyte Inc Stock (MXCT) Company Profile
Nome
Maxcyte Inc
Settore
Industria
Telefono
301-517-5556
Indirizzo
9713 KEY WEST AVENUE,, ROCKVILLE
Confronta MXCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
2.15 | 245.60M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
133.94 | 231.14B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.83 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.10 | 146.12B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.00 | 105.64B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.77 | 45.60B | 5.54B | 4.18B | 623.10M | 7.00 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-29 | Iniziato | Craig Hallum | Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-24 | Iniziato | BTIG Research | Buy |
| 2021-08-24 | Iniziato | Cowen | Outperform |
| 2021-08-24 | Iniziato | Stephens | Overweight |
| 2021-08-24 | Iniziato | Stifel | Buy |
| 2021-08-24 | Iniziato | Wedbush | Outperform |
| 2021-08-24 | Iniziato | William Blair | Outperform |
Mostra tutto
Maxcyte Inc Borsa (MXCT) Ultime notizie
BlackRock Increases Stake in MaxCyte to 9.98% - TipRanks
Nuveen Asset Management LLC Cuts Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
ProShare Advisors LLC Has $143,000 Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
BNP Paribas Financial Markets Takes $56,000 Position in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
BlackRock Increases Stake in MaxCyte - TipRanks
MaxCyte Expands Stock Capital Amidst Strategic Growth - TipRanks
Jane Street Group LLC Purchases 12,209 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte (NASDAQ:MXCT) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Deutsche Bank AG Buys 38,782 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Voting Rights Structure - TipRanks
D. E. Shaw & Co. Inc. Buys 84,105 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Major Shareholder Voting Rights - TipRanks
MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks
BlackRock Increases Stake in MaxCyte, Boosting Voting Rights - TipRanks
BlackRock Increases Stake in MaxCyte to 7.65% - TipRanks
Price T Rowe Associates Inc. MD Has $177,000 Position in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Major Shareholder Holdings - TipRanks
MaxCyte, Inc. (MXCT): A Bull Case Theory - MSN
MaxCyte Inc (MXCT): Be Patient, You Will Learn - Stocksregister
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2025 Earnings Call Transcript - Insider Monkey
MaxCyte’s Earnings Call: Navigating Challenges and Opportunities - TipRanks
William Blair Predicts MaxCyte’s Q2 Earnings (NASDAQ:MXCT) - Defense World
Hsbc Holdings PLC Purchases 16,554 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Files Form 10-Q for Q1 2025 - TipRanks
BTIG cuts MaxCyte stock price target to $5, maintains Buy rating - Investing.com
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates - MSN
MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know - MSN
Earnings call transcript: MaxCyte Q1 2025 beats revenue forecast, stock reacts - Investing.com
Wells Fargo & Company MN Boosts Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance - The Manila Times
MaxCyte Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MaxCyte Reports Q1 2025 Financial Results Amid Revenue Dip - TipRanks
MaxCyte reports Q1 EPS (10c), consensus (10c) - TipRanks
Financial Fitness Check: Examining MaxCyte Inc (MXCT)’s Key Ratios - DWinneX
A Look at MaxCyte's Upcoming Earnings Report - Nasdaq
MaxCyte Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Invesco Ltd. Has $204,000 Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte (MXCT) to Release Quarterly Earnings on Wednesday - Defense World
MaxCyte, Inc. (NASDAQ:MXCT) Position Trimmed by Legal & General Group Plc - Defense World
MaxCyte Expands Stock Capital with New Share Issuance - TipRanks
Upward Trajectory: MaxCyte Inc (MXCT) Posts a Slidee, Closing at 2.84 - DWinneX
A stock that deserves closer examination: MaxCyte Inc (MXCT) - uspostnews.com
Renaissance Technologies LLC Has $1.17 Million Stock Position in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte, Inc. (NASDAQ:MXCT) Shares Sold by JPMorgan Chase & Co. - Defense World
Renaissance Technologies LLC Acquires 91,100 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - The AM Reporter
MaxCyte Announces AIM Delisting to Focus on NASDAQ - TipRanks
MaxCyte Inc (MXCT) requires closer examination - uspostnews.com
BlackRock Adjusts Stake in MaxCyte, Inc. - TipRanks
Maxcyte Inc Azioni (MXCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Maxcyte Inc Azioni (MXCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sandoval David I. | GENERAL COUNSEL |
Mar 18 '25 |
Sale |
3.18 |
353 |
1,122 |
64,219 |
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Mar 18 '25 |
Sale |
3.18 |
6,939 |
22,061 |
111,811 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Sale |
4.64 |
3,000 |
13,935 |
141,950 |
| Sandoval David I. | GENERAL COUNSEL |
Jan 13 '25 |
Sale |
4.54 |
4,466 |
20,272 |
41,447 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Sale |
4.01 |
3,000 |
12,021 |
141,950 |
0.64%
0.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):